Sabby Volatility Fund Discloses 403,233 Share Stake in Revelation Biosciences
Ticker: REVBW · Form: SC 13G · Filed: Jan 3, 2024 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | SC 13G |
| Filed Date | Jan 3, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, SC-13G, beneficial-ownership
TL;DR
**Sabby Fund just revealed a 403,233 share stake in Revelation Biosciences, signaling institutional interest.**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd., a Cayman Islands-based entity, reported beneficial ownership of 403,233 shares of Revelation Biosciences, Inc. common stock as of December 31, 2023. This represents a significant stake, giving them shared voting and dispositive power over these shares. This matters to investors because a large institutional holder like Sabby taking a position can signal confidence in the company's future, potentially influencing other investors and the stock price.
Why It Matters
A major institutional investor, Sabby Volatility Warrant Master Fund, Ltd., has acquired a substantial stake in Revelation Biosciences, Inc., indicating a potential belief in the company's value and future prospects.
Risk Assessment
Risk Level: low — This filing indicates a new institutional investor, which is generally a positive signal and does not inherently increase risk for current shareholders.
Analyst Insight
A smart investor would note this institutional accumulation as a potential positive signal and consider further due diligence into Revelation Biosciences, Inc.'s fundamentals and future prospects.
Key Numbers
- 403,233 — Shares Beneficially Owned (Represents the total number of Revelation Biosciences, Inc. common stock shares Sabby Volatility Warrant Master Fund, Ltd. has shared voting and dispositive power over.)
- December 31, 2023 — Date of Event (The specific date on which the beneficial ownership requiring this filing was established.)
- 76135L101 — CUSIP Number (Unique identifier for Revelation Biosciences, Inc. Common Stock.)
Key Players & Entities
- Sabby Volatility Warrant Master Fund, Ltd. (company) — reporting person, beneficial owner of shares
- Revelation Biosciences, Inc. (company) — subject company, issuer of common stock
- Sabby Management, LLC (company) — filer of the SC 13G
- Cayman Islands (company) — place of organization for Sabby Volatility Warrant Master Fund, Ltd.
Forward-Looking Statements
- Revelation Biosciences, Inc. stock may experience increased trading volume due to institutional interest. (Revelation Biosciences, Inc.) — medium confidence, target: Q1 2024
- Other institutional investors might follow Sabby's lead and initiate positions in Revelation Biosciences, Inc. (Revelation Biosciences, Inc.) — low confidence, target: Mid 2024
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is Sabby Volatility Warrant Master Fund, Ltd., as stated in Item 1 of the filing.
What is the name of the issuer whose securities are being reported?
The issuer is Revelation Biosciences, Inc., as identified in the 'Name of Issuer' section of the filing.
How many shares of Revelation Biosciences, Inc. common stock does the reporting person beneficially own?
The reporting person, Sabby Volatility Warrant Master Fund, Ltd., beneficially owns 403,233 shares, as indicated in Item 6 and 8 of the cover page for shared voting and dispositive power.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as marked with an 'X' in the 'Check the appropriate box' section.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 3, 2024 regarding REVELATION BIOSCIENCES, INC. (REVBW).